Argenx SE (NASDAQ:ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).
Argenx reported fourth-quarter earnings of $8.02 per share, beating the consensus of $6.02. Sales jumped from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion.
“Argenx delivered another standout year of execution in 2025,” said Tim Van Hauwermeiren, CEO of Argenx. “We reached 19,000 patients globally with VYVGART, expanded our impact across gMG and CIDP through the successful launch of the pre-filled syringe, and made substantial progress across our development programs, advancing the pipeline towards key milestones.”
Argenx shares closed at $771.53 on Thursday.
These analysts made changes to their price targets on Argenx following earnings announcement.
- HC Wainwright & Co. analyst Douglas Tsao maintained argenx with a Buy and raised the price target from $915 to $940.
- Baird analyst Colleen Kusy maintained the stock with a Neutral and raised the price target from $858 to $867.
- Guggenheim analyst Yatin Suneja maintained argenx with a Buy and cut the price target from $1,160 to $1,120.
- Citizens analyst Jason N. Butler maintained the stock with a Market Outperform and raised the price target from $925 to $944.
Considering buying ARGX stock? Here’s what analysts think:
Photo via Shutterstock